Join us and special guest John McDermott at Fusion: Shamrock Shenanigans!Read More
Take Action Now
On Thursday 4 October 2018, the Canadian Agency for Drugs and Technologies in Health (CADTH) recommended that the cystic fibrosis (CF) drug ORKAMBI not be reimbursed by federal, provincial, and territorial drug programs. Quebec has a separate review body – INESSS – from which a decision is expected soon. As well, the British Columbia Pharmacare program is undertaking its own review, as may other provinces be.
The CADTH recommendation is non-binding, so our governments may do what they want with it. This is why we must take action now. Tell your health minister to grant access to Orkambi to improve the lives of those living with CF.
Tell your health minister to grant access to Orkambi now
Many Canadians don’t know this, but the CADTH recommendations are non-binding. Your provincial health minister can still do the right thing and grant access to Orkambi in your province. Find your minister’s contact details below and contact them today. Download our PDF of helpful talking points about Orkambi to help with your conversation or message. For more information on the CADTH decision and Orkambi, visit our Orkambi webpage.
Contact your Health Minister:
HONOURABLE SARAH HOFFMAN
Minister of Health
Office of the Minister
423 Legislature Building
10800 - 97 Avenue
Honourable Benoît Bourque
520 King Street
Honourable Dr. John Haggie
Department of Health and Community Services
P.O. Box 8700
1st Floor, West Block
100 Prince Philip Drive
St. John's, NL A1B 4J6
Honourable Randy Delorey
Department of Health and Wellness
17th Floor, Barrington Tower
1894 Barrington Street
P.O. Box 488
Halifax, Nova Scotia
Honourable george Hickes
Government of Nunavut
P.O. Box 2410
Iqaluit, NU X0A 0H0
HONOURABLE ROBERT MITCHELL
4th Floor, Shaw Building North
105 Rochford Street
P.O. Box 2000
Honourable Gaétan Barrette
Ministère de la Santé et des Services sociaux
1075 Ch. Sainte-Foy, 15th Floor
A new CF drug has the potential to significantly improve the lives of many people with CF. It is imperative the drug is covered by public and private drug plans.
Although Orkambi™ could potentially help 50% of the Canadian CF population, ensuring that Orkambi™ is covered by public and private drug plans is important not just for the people for whom Orkambi™ is for. It is important to all of the CF community because we know that in the coming years there are going to be many new drugs. Drug access today will impact drug access tomorrow.
We must take action now so that decision-makers understand CF, appreciate the expertise of CF physicians who are prescribing these life-changing drugs, and commit to ensuring all people with CF have access to the best medicines available to them.
BECOME AN ADVOCATE
CF Advocates can have a significant impact on the way CF issues are addressed in Canada by all levels of government. Working with CF Canada, advocates build relationships with elected and appointed officials in order to increase support for programs, services and policies that can improve the quality of life for people with cystic fibrosis.
For more information, contact email@example.com.
ORKAMBI ADVOCATE’S TOOL KIT
- Orkambi™ call to action flyer (PDF download)
- Tips for meeting with elected officials (PDF download)
- Our recommendations for the clinical use of Orkambi™ (PDF download)